Description

Abbott Laboratories: A Tale Of Pipeline Productivity and Innovation!

Abbott has demonstrated robust performance in its third quarter of 2024 with an organic sales growth of over 8%, excluding COVID testing sales, and adjusted earnings per share of $1.21. These results underscore the company’s capacity to execute its multifaceted strategy effectively, despite varying performance across different sectors. Notably, the U.S. Pediatric Nutrition segment showed remarkable growth, leading with a 12% increase due to gains in the infant formula business. Similarly, Abbott’s U.S. Adult Nutrition also grew by 11.5%, driven by its popular Ensure and Glucerna brands. These segments underscore the company’s stronghold in the nutrition sector, benefiting from a growing global demand for health-optimized products.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!